Novo Nordisk to cut insulin prices in the U.S.
COPENHAGEN (Reuters) – Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and…
Drugmakers file second court challenge to Canada’s new drug price rules
TORONTO (Reuters) – Canada’s main pharmaceutical industry lobby group, along with 16 of its member companies, filed a lawsuit on Friday to block new regulations meant to lower patented drug…
FDA approves Boehringer’s lung disease drug
(Reuters) – The U.S. Food and Drug Administration on Friday approved German drugmaker Boehringer Ingelheim’s Ofev capsules for a rare lung disorder. The drug is first FDA-approved treatment for this…
U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta
(Reuters) – The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co’s lung cancer drug Alimta. Shares of…
Trump presses U.S. companies to close China operations
WASHINGTON (Reuters) – President Donald Trump said on Friday he was ordering U.S. companies to look at ways to close their operations in China and make more of their products…
Companies file suit in Canada challenging new rules to lower drug prices
(Reuters) – Five pharmaceutical companies said on Friday they have filed a complaint in a Canadian court challenging the constitutionality of new Canadian regulations meant to lower patented drug prices,…
Trump administration to appeal ruling blocking price disclosure for drug ads
FILE PHOTO: Bottles of drugs sit on the shelf at the Rock Canyon Pharmacy, in Provo, Utah, U.S., May 9, 2019. REUTERS/GEORGE FREY (Reuters) – The Trump administration is appealing…
Cardinal Health warns ongoing opioid-related lawsuits to hit business
(Reuters) – Drug distributor Cardinal Health Inc (CAH.N) warned on Tuesday that its business could be hurt as it defends itself against several opioid-related lawsuits. Several pharmaceutical wholesale distributors, including…
FDA declines to approve Sarepta’s second Duchenne treatment
(Reuters) – Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the…
AbbVie prices new rheumatoid arthritis drug at $59,000 a year
(Reuters) – AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising…